Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab
BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.Objectives...
Gespeichert in:
| Veröffentlicht in: | Pediatric dermatology 2024-01, Vol.41 (1), p.5-11 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 1 |
| container_start_page | 5 |
| container_title | Pediatric dermatology |
| container_volume | 41 |
| creator | Sylvia Martinez‐Cabriales Marcoux, Danielle Carmen Liy‐Wong Prajapati, Vimal H Sibbald, Cathryn Cunningham, Natalie Lansang, Perla Tonkin, Rochelle Joseph, Marissa Wong, Lauren Spring, Shanna Gavigan, Genevieve Ramien, Michele |
| description | BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.ObjectivesTo describe the real‐world effectiveness and safety in patients aged 2 to |
| doi_str_mv | 10.1111/pde.15418 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2919348586</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2919348586</sourcerecordid><originalsourceid>FETCH-proquest_journals_29193485863</originalsourceid><addsrcrecordid>eNqNjDtOxEAMhkcIJMKj4AaWqLPM5LXZegWiodt-ZRIvO6skM4wdEB1HoOCEnAQLOAAubOn_P3_GXDm7cDo3saeFqyvXHpnM1UWdu2ppj01ml2WTt7ZqTs0Z88Fa2zaNy8znwzyI72gSSrDGCXuPE3TIBEzJE0PYQSRNJfkOIopXlmEgZpC9sq54I0w_HD4RvHrZwxh6Sij09f4hQRfTCyUClBBVot2oHvFqSKRY__vVz9EP84iPF-ZkhwPT5d89N9d3t5v1fR5TeJ6JZXsIc5q02hYrtyqrtm6b8n_UN403YB8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2919348586</pqid></control><display><type>article</type><title>Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab</title><source>Wiley-Blackwell Journals</source><creator>Sylvia Martinez‐Cabriales ; Marcoux, Danielle ; Carmen Liy‐Wong ; Prajapati, Vimal H ; Sibbald, Cathryn ; Cunningham, Natalie ; Lansang, Perla ; Tonkin, Rochelle ; Joseph, Marissa ; Wong, Lauren ; Spring, Shanna ; Gavigan, Genevieve ; Ramien, Michele</creator><creatorcontrib>Sylvia Martinez‐Cabriales ; Marcoux, Danielle ; Carmen Liy‐Wong ; Prajapati, Vimal H ; Sibbald, Cathryn ; Cunningham, Natalie ; Lansang, Perla ; Tonkin, Rochelle ; Joseph, Marissa ; Wong, Lauren ; Spring, Shanna ; Gavigan, Genevieve ; Ramien, Michele</creatorcontrib><description>BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.ObjectivesTo describe the real‐world effectiveness and safety in patients aged <12 years with moderate‐severe AD currently receiving or previously having received dupilumab.MethodsA multicenter retrospective study was conducted at six Canadian sites. Cases were divided into Group 1 ≤2 years old, Group 2 >2 to <6 years old, and Group 3 ≥6 to <12 years old. Medical history and details of dupilumab treatment were collected. The primary outcome was to measure the improvement in eczema area and severity index. Secondary outcomes examined included the children's dermatology life quality index/infant's dermatitis quality of life, peak pruritus numerical rating scale, and delay to dupilumab access for patients who were considered off‐label for dupilumab due to their age.ResultsSixty three pediatric patients (37 males) with moderate‐to‐severe AD were included; the mean age was 6.4 years old (range: 2–11) when dupilumab treatment was started. Overall, 75% (36/48) achieved EASI‐75% and 71% (34/48) achieved EASI‐90. EASI‐75 and EASI‐90 were achieved in 90% (17/19) and 73% (12/19) in patients <6 years old, and 76% (22/29) and 59% (17/29) in patients >6 years old, respectively. No serious adverse events were reported.ConclusionsDupilumab is safe and effective for patients under the age of 12. However, even for experienced providers, access to the medication was challenging.</description><identifier>ISSN: 0736-8046</identifier><identifier>EISSN: 1525-1470</identifier><identifier>DOI: 10.1111/pde.15418</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc</publisher><subject>Age ; Atopic dermatitis ; Dermatitis ; Dermatology ; Eczema ; FDA approval ; Monoclonal antibodies ; Patients ; Pediatrics ; Pruritus ; Quality of life</subject><ispartof>Pediatric dermatology, 2024-01, Vol.41 (1), p.5-11</ispartof><rights>2023. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Sylvia Martinez‐Cabriales</creatorcontrib><creatorcontrib>Marcoux, Danielle</creatorcontrib><creatorcontrib>Carmen Liy‐Wong</creatorcontrib><creatorcontrib>Prajapati, Vimal H</creatorcontrib><creatorcontrib>Sibbald, Cathryn</creatorcontrib><creatorcontrib>Cunningham, Natalie</creatorcontrib><creatorcontrib>Lansang, Perla</creatorcontrib><creatorcontrib>Tonkin, Rochelle</creatorcontrib><creatorcontrib>Joseph, Marissa</creatorcontrib><creatorcontrib>Wong, Lauren</creatorcontrib><creatorcontrib>Spring, Shanna</creatorcontrib><creatorcontrib>Gavigan, Genevieve</creatorcontrib><creatorcontrib>Ramien, Michele</creatorcontrib><title>Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab</title><title>Pediatric dermatology</title><description>BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.ObjectivesTo describe the real‐world effectiveness and safety in patients aged <12 years with moderate‐severe AD currently receiving or previously having received dupilumab.MethodsA multicenter retrospective study was conducted at six Canadian sites. Cases were divided into Group 1 ≤2 years old, Group 2 >2 to <6 years old, and Group 3 ≥6 to <12 years old. Medical history and details of dupilumab treatment were collected. The primary outcome was to measure the improvement in eczema area and severity index. Secondary outcomes examined included the children's dermatology life quality index/infant's dermatitis quality of life, peak pruritus numerical rating scale, and delay to dupilumab access for patients who were considered off‐label for dupilumab due to their age.ResultsSixty three pediatric patients (37 males) with moderate‐to‐severe AD were included; the mean age was 6.4 years old (range: 2–11) when dupilumab treatment was started. Overall, 75% (36/48) achieved EASI‐75% and 71% (34/48) achieved EASI‐90. EASI‐75 and EASI‐90 were achieved in 90% (17/19) and 73% (12/19) in patients <6 years old, and 76% (22/29) and 59% (17/29) in patients >6 years old, respectively. No serious adverse events were reported.ConclusionsDupilumab is safe and effective for patients under the age of 12. However, even for experienced providers, access to the medication was challenging.</description><subject>Age</subject><subject>Atopic dermatitis</subject><subject>Dermatitis</subject><subject>Dermatology</subject><subject>Eczema</subject><subject>FDA approval</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pruritus</subject><subject>Quality of life</subject><issn>0736-8046</issn><issn>1525-1470</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqNjDtOxEAMhkcIJMKj4AaWqLPM5LXZegWiodt-ZRIvO6skM4wdEB1HoOCEnAQLOAAubOn_P3_GXDm7cDo3saeFqyvXHpnM1UWdu2ppj01ml2WTt7ZqTs0Z88Fa2zaNy8znwzyI72gSSrDGCXuPE3TIBEzJE0PYQSRNJfkOIopXlmEgZpC9sq54I0w_HD4RvHrZwxh6Sij09f4hQRfTCyUClBBVot2oHvFqSKRY__vVz9EP84iPF-ZkhwPT5d89N9d3t5v1fR5TeJ6JZXsIc5q02hYrtyqrtm6b8n_UN403YB8</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>Sylvia Martinez‐Cabriales</creator><creator>Marcoux, Danielle</creator><creator>Carmen Liy‐Wong</creator><creator>Prajapati, Vimal H</creator><creator>Sibbald, Cathryn</creator><creator>Cunningham, Natalie</creator><creator>Lansang, Perla</creator><creator>Tonkin, Rochelle</creator><creator>Joseph, Marissa</creator><creator>Wong, Lauren</creator><creator>Spring, Shanna</creator><creator>Gavigan, Genevieve</creator><creator>Ramien, Michele</creator><general>Wiley Subscription Services, Inc</general><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20240101</creationdate><title>Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab</title><author>Sylvia Martinez‐Cabriales ; Marcoux, Danielle ; Carmen Liy‐Wong ; Prajapati, Vimal H ; Sibbald, Cathryn ; Cunningham, Natalie ; Lansang, Perla ; Tonkin, Rochelle ; Joseph, Marissa ; Wong, Lauren ; Spring, Shanna ; Gavigan, Genevieve ; Ramien, Michele</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_29193485863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Age</topic><topic>Atopic dermatitis</topic><topic>Dermatitis</topic><topic>Dermatology</topic><topic>Eczema</topic><topic>FDA approval</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pruritus</topic><topic>Quality of life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sylvia Martinez‐Cabriales</creatorcontrib><creatorcontrib>Marcoux, Danielle</creatorcontrib><creatorcontrib>Carmen Liy‐Wong</creatorcontrib><creatorcontrib>Prajapati, Vimal H</creatorcontrib><creatorcontrib>Sibbald, Cathryn</creatorcontrib><creatorcontrib>Cunningham, Natalie</creatorcontrib><creatorcontrib>Lansang, Perla</creatorcontrib><creatorcontrib>Tonkin, Rochelle</creatorcontrib><creatorcontrib>Joseph, Marissa</creatorcontrib><creatorcontrib>Wong, Lauren</creatorcontrib><creatorcontrib>Spring, Shanna</creatorcontrib><creatorcontrib>Gavigan, Genevieve</creatorcontrib><creatorcontrib>Ramien, Michele</creatorcontrib><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Pediatric dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sylvia Martinez‐Cabriales</au><au>Marcoux, Danielle</au><au>Carmen Liy‐Wong</au><au>Prajapati, Vimal H</au><au>Sibbald, Cathryn</au><au>Cunningham, Natalie</au><au>Lansang, Perla</au><au>Tonkin, Rochelle</au><au>Joseph, Marissa</au><au>Wong, Lauren</au><au>Spring, Shanna</au><au>Gavigan, Genevieve</au><au>Ramien, Michele</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab</atitle><jtitle>Pediatric dermatology</jtitle><date>2024-01-01</date><risdate>2024</risdate><volume>41</volume><issue>1</issue><spage>5</spage><epage>11</epage><pages>5-11</pages><issn>0736-8046</issn><eissn>1525-1470</eissn><abstract>BackgroundDupilumab is approved for moderate‐severe atopic dermatitis (AD) in patients aged ≥6 months by the US Food and Drug Administration and Health Canada; however, there are little real‐world data because providers have limited practical experience with this recently approved therapy.ObjectivesTo describe the real‐world effectiveness and safety in patients aged <12 years with moderate‐severe AD currently receiving or previously having received dupilumab.MethodsA multicenter retrospective study was conducted at six Canadian sites. Cases were divided into Group 1 ≤2 years old, Group 2 >2 to <6 years old, and Group 3 ≥6 to <12 years old. Medical history and details of dupilumab treatment were collected. The primary outcome was to measure the improvement in eczema area and severity index. Secondary outcomes examined included the children's dermatology life quality index/infant's dermatitis quality of life, peak pruritus numerical rating scale, and delay to dupilumab access for patients who were considered off‐label for dupilumab due to their age.ResultsSixty three pediatric patients (37 males) with moderate‐to‐severe AD were included; the mean age was 6.4 years old (range: 2–11) when dupilumab treatment was started. Overall, 75% (36/48) achieved EASI‐75% and 71% (34/48) achieved EASI‐90. EASI‐75 and EASI‐90 were achieved in 90% (17/19) and 73% (12/19) in patients <6 years old, and 76% (22/29) and 59% (17/29) in patients >6 years old, respectively. No serious adverse events were reported.ConclusionsDupilumab is safe and effective for patients under the age of 12. However, even for experienced providers, access to the medication was challenging.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/pde.15418</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0736-8046 |
| ispartof | Pediatric dermatology, 2024-01, Vol.41 (1), p.5-11 |
| issn | 0736-8046 1525-1470 |
| language | eng |
| recordid | cdi_proquest_journals_2919348586 |
| source | Wiley-Blackwell Journals |
| subjects | Age Atopic dermatitis Dermatitis Dermatology Eczema FDA approval Monoclonal antibodies Patients Pediatrics Pruritus Quality of life |
| title | Multicenter Canadian case series of pediatric patients less than 12years of age with moderate‐to‐severe atopic dermatitis treated with dupilumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A35%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicenter%20Canadian%20case%20series%20of%20pediatric%20patients%20less%20than%2012years%20of%20age%20with%20moderate%E2%80%90to%E2%80%90severe%20atopic%20dermatitis%20treated%20with%20dupilumab&rft.jtitle=Pediatric%20dermatology&rft.au=Sylvia%20Martinez%E2%80%90Cabriales&rft.date=2024-01-01&rft.volume=41&rft.issue=1&rft.spage=5&rft.epage=11&rft.pages=5-11&rft.issn=0736-8046&rft.eissn=1525-1470&rft_id=info:doi/10.1111/pde.15418&rft_dat=%3Cproquest%3E2919348586%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2919348586&rft_id=info:pmid/&rfr_iscdi=true |